Harvard Apparatus Regenerative Technology, Inc. cotiza a 2.12 USD y tiene una capitalización bursátil de $43M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Consumo defensivo
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Impla…
| Periodo | 2017-08 | 2017-05 | 2017-03 | 2016-11 |
|---|---|---|---|---|
| Real | $-2.00 | $-2.80 | $-4.00 | $-3.60 |
| Estimado | $-1.40 | $-2.20 | $-4.20 | $-5.00 |
| Sorpresa | -42.9% | -27.3% | +4.8% | +28.0% |
| Métrica | HRGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 8.2% | 30.7% | -22.4% |
| Operating Margin | -982.2% | 1.0% | -983.3% |
| Net Margin | -975.7% | 0.8% | -976.5% |
| FCF Margin | — | 2.4% | — |
| ROE | -649.9% | 5.2% | -655.0% |
| ROA | -256.6% | 0.6% | -257.2% |
| Current Ratio | 1.19 | 1.35 | -0.16 |
| Debt / Equity | — | 0.37 | — |